Drug Store News - FluLaval from GlaxoSmithKline will be available this fall to treat the strain of influenza that is expected to drive tins season’s flu activity in North America
FluLaval from GlaxoSmithKline will be available this fall to treat the strain of influenza that is expected to drive tins season’s flu activity in North America. This means there are now five FDA-approved vaccines to treat flu for winter 2006-2007.
FluLaval was approved using the FDA’s accelerated approval pathway, through which the agency clears products for serious or life-threatening diseases.
The Centers for Disease Control and Prevention have projected making approximately 115 million doses of vaccine this year. The CDC states that every year, 5 percent to 20 percent of the population contracts the flu, 200,000 people are hospitalized from it and 36,000 die.
Related Results
LamictalGSK launches LamictalStudy backs Lamictal XRGeneric Lamictal approvedLamictal:
In other company news, the FDA has approved GSK’s anti-seizure medicine Lamictal (lamotrigine) tablets to treat one of the most serious forms of epilepsy. The drug now can be used as an add-on therapy to treat primary generalized tonic-clonic–or grand mal–seizures in children age 2 and older, as well as adults.
This is the fifth approval for Lamictal in epilepsy, which makes it one of the few antiepileptic drugs with established efficacy in a broadspectrum of seizure types.
COPYRIGHT 2006 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2008 Gale, Cengage Learning
